Varex Imaging Corp (VREX) Stock Price & Analysis
Varex Imaging Corp (VREX) rose 3.21% to USD 10.62 as of June 10, 2026 at 02:40 UTC, according to Nexqual real-time market data.
VREX last closed at USD 10.29; the session ranged USD 10.42–10.71 on volume of 268,234 shares. Market capitalization is $447.60M, with a 52-week range of USD 6.76–14.57 (NMS). Source: Nexqual, June 10, 2026 at 02:40 UTC.
Key Statistics (as of June 10, 2026 at 02:40 UTC)
| Price | USD 10.62 |
|---|---|
| Change | ▲ 3.21% (up) |
| Previous Close | USD 10.29 |
| Open | USD 10.42 |
| Day Range | USD 10.42 – 10.71 |
| 52-Week Range | USD 6.76 – 14.57 |
| Volume | 268,234 shares |
| Market Cap | $447.60M |
| Exchange | NMS |
Technical Analysis (VREX)
Nexqual's technical model rates VREX "SELL" based on 2 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 02:40 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 50.15 (neutral) |
| vs SMA50 | Below (USD 10.87) |
| MACD | -0.16 (negative) |
Analyst Ratings (VREX)
Wall Street analysts rate VREX "Buy" based on 5 analysts, with a mean price target of USD 18 (range USD 12–22), per Nexqual as of June 10, 2026 at 02:40 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 18 |
| High Target | USD 22 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (VREX)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 0.2 |
| Revenue Estimate | $215.50M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.21 vs est 0.21 ▲ beat |
| 2025-12-31 | USD 0.19 vs est 0.13 ▲ beat |
| 2025-09-30 | USD 0.37 vs est 0.18 ▲ beat |
| 2025-06-30 | USD 0.18 vs est 0.04 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:40 UTC.
Financials & Fundamentals (VREX)
| Total Revenue | $857.50M |
|---|---|
| Revenue Growth (YoY) | +1.50% |
| Gross Margin | +33.55% |
| Operating Margin | +6.67% |
| Profit Margin | -9.64% |
| ROE | -15.68% |
| Debt / Equity | 78.06 |
| Current Ratio | 3.2 |
| Total Cash | $88.30M |
| Total Debt | $381.00M |
| Free Cash Flow | $-40.27M |
Source: Nexqual, June 10, 2026 at 02:40 UTC.
Financial Health Score (VREX)
Nexqual rates Varex Imaging Corp's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:40 UTC.
| Growth | Mixed — Revenue +4.1% YoY (annual), slow |
|---|---|
| Profitability | Solid — Gross margin 34%, operating 7% |
| Balance Sheet | Mixed — $88M cash vs $381M debt |
| Cash Flow | Weak — FCF negative: -$40M, burning cash |
| Efficiency | Critical — ROE -16%, ROA 3.2% |
Ownership (VREX)
| Insider Ownership | +1.66% |
|---|---|
| Institutional Ownership | +101.29% |
| Shares Outstanding | 42.15M |
| Float | 41.40M |
| Short % of Float | +3.15% |
Source: Nexqual, June 10, 2026 at 02:40 UTC.
Leadership (VREX)
Varex Imaging Corp is led by Sunny S. Sanyal (age 61), President, CEO & Director, per Nexqual as of June 10, 2026 at 02:40 UTC.
| President, CEO & Director | Sunny S. Sanyal (age 61) |
|---|---|
| CFO & Principal Accounting Officer | Shubham Maheshwari (age 54) |
| Senior VP & GM of X-Ray Detectors | Andrew J. Hartmann (age 62) |
| Director of Investor Relations | Christopher John Belfiore |
| Senior Vice President of Regulatory & Quality Compliance | Victor Garcia |
Major Backers & Investors (VREX)
Notable institutional backers of Varex Imaging Corp include Pzena Investment Management LLC, Allspring Global Investments Holdings, LLC, Neuberger Berman Group, LLC, according to Nexqual as of June 10, 2026 at 02:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Pzena Investment Management LLC | 9.48% |
| Allspring Global Investments Holdings, LLC | 6.29% |
| Neuberger Berman Group, LLC | 5.78% |
| ALLSPRING FUNDS TRUST-Allspring Special Small Cap Value Fund | 4.51% |
| LSV Asset Management | 4.19% |
| Cooke & Bieler LP | 3.1% |
| Rice, Hall, James & Associates LLC | 3.03% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.39% |
| Vanguard Group | 8.54% |
| Dimensional Fund Advisors | 3.7% |
Source: Nexqual, June 10, 2026 at 02:40 UTC.
From Varex Imaging Corp's Latest SEC 10-K Filing (filed 2025-11-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Our manufacturing operations for medical devices, and those of our third-party manufacturers, are required to comply with the FDA's Quality System Regulation ("QSR"), which addresses a company's responsibility for product design, testing, and manufacturing quality assurance, and the maintenance of records and documentation.
- As a participant in the healthcare industry, we are also subject to extensive laws and regulations protecting the privacy and integrity of patient medical information that we receive, including the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), new state privacy laws, "fraud and abuse" laws and regulations, including physician self-referral prohibitions, and false claims laws.
- As of October 3, 2025, we own approximately 240 patents issued in the United States, approximately 420 patents issued throughout the rest of the world and have approximately 210 patent applications pending with various patent agencies worldwide.
- Shubham (Sam) joined Varex from SiFive, Inc., a leading provider of hardware and software solutions for developing RISC-V based processors and semiconductor chips, where he served as CFO.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LIVN | LivaNova PLC | USD 77.17 | ▲ 6.65% |
| KIDS | OrthoPediatrics Corp. | USD 18.49 | ▲ 0.93% |
| MLAB | Mesa Laboratories, Inc. | USD 109.03 | ▲ 4.95% |
| OFIX | Orthofix Medical Inc. | USD 9.87 | ▼ 4.08% |
| AVNS | Avanos Medical, Inc. | USD 25.03 | ▼ 0.08% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:40 UTC. This page is informational and not investment advice.